Summary: The US FDA has approved Nyxoah SA’s Genio hypoglossal nerve stimulator for adults with moderate to severe OSA (AHI 15–65). Key takeaways:The Genio wearable controller is upgradable, avoiding additional surgeries for technology or battery updates. DREAM pivotal trial showed consistent efficacy across sleeping positions, including the challenging supine position. The wearable component is upgradable, providing Genio patients with access to this technology without requiring additional surgeries for technology updates or battery replacements. “Our mission has always been to make sleep simple for OSA patients by offering them a solution that empowers better sleep.